SEAGEN INC (SGEN) Stock Price, Quote, News and Overview
NASDAQ:SGEN - Nasdaq - US81181C1045 - Common Stock - Currency: USD
SGEN Quote, Performance and Key Statistics
228.74
-0.16 (-0.07%)
The current stock price of SGEN is 228.74 USD. In the past month the price increased by 6.91%. In the past year, price increased by 76.48%.
SGEN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About SGEN
Company Profile
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. The company is headquartered in Bothell, Washington and currently employs 3,256 full-time employees. The company went IPO on 2001-03-07. The firm is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. The company is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
Company Info
SEAGEN INC
21823 30Th Drive Se, Suite
Bothell WASHINGTON 98021 US
CEO: Clay B. Siegall
Employees: 3256
Company Website: https://www.seagen.com/
Phone: 14255274000
SEAGEN INC / SGEN FAQ
What is the stock price of SEAGEN INC today?
The current stock price of SGEN is 228.74 USD. The price decreased by -0.07% in the last trading session.
What is the ticker symbol for SEAGEN INC stock?
The exchange symbol of SEAGEN INC is SGEN and it is listed on the Nasdaq exchange.
On which exchange is SGEN stock listed?
SGEN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SEAGEN INC stock?
23 analysts have analysed SGEN and the average price target is 233.48 USD. This implies a price increase of 2.07% is expected in the next year compared to the current price of 228.74. Check the SEAGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SEAGEN INC worth?
SEAGEN INC (SGEN) has a market capitalization of 43.15B USD. This makes SGEN a Large Cap stock.
How many employees does SEAGEN INC have?
SEAGEN INC (SGEN) currently has 3256 employees.
What are the support and resistance levels for SEAGEN INC (SGEN) stock?
SEAGEN INC (SGEN) has a support level at 218.72. Check the full technical report for a detailed analysis of SGEN support and resistance levels.
Is SEAGEN INC (SGEN) expected to grow?
The Revenue of SEAGEN INC (SGEN) is expected to grow by 28.4% in the next year. Check the estimates tab for more information on the SGEN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SEAGEN INC (SGEN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SGEN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SGEN, evaluating the profitability, health, valuation and growth aspects
- SEAGEN INC (SGEN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SEAGEN INC (SGEN) Sales and EPS estimates to see what analysts future expectations are.
- SEAGEN INC (SGEN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SEAGEN INC (SGEN) Insider and Institutional Ownership to learn about the owners and their transactions.
- SEAGEN INC (SGEN) Stock Chart to make your own analysis
- SEAGEN INC (SGEN) Latest news and press-releases to stay up to date.
Does SEAGEN INC (SGEN) stock pay dividends?
SGEN does not pay a dividend.
When does SEAGEN INC (SGEN) report earnings?
SEAGEN INC (SGEN) will report earnings on 2024-02-13, after the market close.
What is the Price/Earnings (PE) ratio of SEAGEN INC (SGEN)?
SEAGEN INC (SGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.01).
SGEN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SGEN. When comparing the yearly performance of all stocks, SGEN is one of the better performing stocks in the market, outperforming 91.69% of all stocks.
SGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SGEN. SGEN has a great financial health rating, but its profitability evaluates not so good.
SGEN Financial Highlights
Over the last trailing twelve months SGEN reported a non-GAAP Earnings per Share(EPS) of -4.01. The EPS decreased by -16.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.64% | ||
| ROE | -29.41% | ||
| Debt/Equity | 0 |
SGEN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 72% to SGEN. The Buy consensus is the average rating of analysts ratings from 23 analysts.
For the next year, analysts expect an EPS growth of -28.74% and a revenue growth 28.4% for SGEN